Respiratory Medicines · LP-067
Beclometasone Inhaler
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-067Respiratory Medicines
- Generic identity
- BeclometasoneInhaler
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-067
- Generic identity
- Beclometasone
- Presentation
- Inhaler
- Catalogue strength
- 50 mcg/dose; 100 mcg/dose; 250 mcg/dose
- Catalogue pack
- Metered-dose inhaler
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: Beclometasone.
- Dosage form: Inhaler.
- Catalogue strength / concentration: 50 mcg/dose; 100 mcg/dose; 250 mcg/dose.
- Catalogue pack: Metered-dose inhaler.
- Catalogue category: Respiratory Medicines; navigation placement is not authorisation evidence.
Layer 02 · Unresolved product-specific fields
- Exact inhaler model/canister/actuator and dose-count specification.
- Metered-versus-delivered dose basis, particle/aerosol characteristics, priming/cleaning and spacer compatibility.
- Approved indication, patient eligibility, dose/administration and contraindication wording for the exact product/jurisdiction.
- Storage conditions, shelf life, registration/market status, manufacturing route and current supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 50 mcg/dose | Metered-dose inhaler | — | Catalogue identifies a metered-dose inhaler; model and strength-specific SKU mapping not supplied | Do not infer delivered dose, aerosol equivalence, actuation count or spacer compatibility. |
| B | 100 mcg/dose | Metered-dose inhaler | — | Catalogue identifies a metered-dose inhaler; model and strength-specific SKU mapping not supplied | Do not infer delivered dose, aerosol equivalence, actuation count or spacer compatibility. |
| C | 250 mcg/dose | Metered-dose inhaler | — | Catalogue identifies a metered-dose inhaler; model and strength-specific SKU mapping not supplied | Do not infer delivered dose, aerosol equivalence, actuation count or spacer compatibility. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Beclometasone is a corticosteroid used in inhaled formulations to reduce airway inflammation. Its role is preventive control, not immediate reversal of a severe asthma attack. Different inhaler designs and formulations can deliver the medicine differently. This educational ingredient profile does not establish Luang Pharma approved indications, device performance or equivalence; the exact inhaler and authorized instructions are essential to clinical selection.
Clinical context and therapeutic role
An inhaled corticosteroid is considered within a respiratory management plan based on diagnosis, symptoms and risk of exacerbations. A clinician or pharmacist should assess technique, adherence and whether a spacer is compatible with the device. A stated amount per actuation is not enough to judge dose equivalence across inhalers. Follow-up considers control, adverse effects and the need for adjustments. The patient also needs a clear plan for worsening symptoms and acute attacks.
Selected safety context
Oral candidiasis, hoarseness and throat irritation can occur. Rinsing the mouth after use is commonly advised when appropriate to the authorized instructions. Excessive systemic exposure can affect adrenal function, growth, bone health or eyes, especially with prolonged higher exposure or interacting medicines. Worsening wheeze immediately after use needs assessment. Do not abruptly change a prescribed steroid plan. Severe breathing difficulty requires the patient’s emergency plan and urgent medical care.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue identifies an inhaler, but the exact device technology, formulation and delivered-versus-metered dose basis require confirmation. Patient technique and device compatibility materially affect delivery. A stated amount per actuation is not proof of equivalence between different inhalers, nor of compatibility with a particular spacer.
Follow the supplied instructions for priming, cleaning, dose counting and storage. Keep any protective cap in place as directed and inspect the device for damage. A pharmacist or trained professional should demonstrate technique; device components should not be substituted across manufacturers without confirmation.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A respiratory-care professional should verify the diagnosis, inhaled-versus-oral role, exact device and technique where applicable. The patient requires a clear plan for worsening symptoms, with regular review of control and adverse effects.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Controlled strength/form/pack SKU matrix and packaging artwork where more than one variant or presentation is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07d checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| NHS: Beclometasone inhalers — clinical backgroundArchived source classification: public-health medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
| NHS: Beclometasone inhalers — side effectsArchived source classification: public-health medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-067.
Professional enquiries
Request product-specific evidence for LP-067.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.